Pfizer (PFE) Declares $0.43 Quarterly Dividend; 6.8% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equities rebound to close higher as surging Treasury yields recede
Goldman Sachs Reiterates Buy Rating on Pfizer (PFE)
December 16, 2024 4:14 AM ESTGoldman Sachs analyst Chris Shibutani reiterated a Buy rating and $33.00 price target on Pfizer (NYSE: PFE).
The analyst comments "Ahead of PFE's 2025 Guidance call (Tuesday, December 17) we outline our expectations for the guide and commentary on the upcoming year. Overall, we anticipate that PFE management will guide to earnings (EPS) in the mid-to-high $2 range with core business growth offset by... More
